PDF(Pubmed)
Abstract：
BACKGROUND: The aim of this study was to investigate changes in macular perfusion in patients affected by diabetic macular edema (DME) and treated with ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg using optical coherence tomography angiography (OCTA).
METHODS: This was a retrospective cohort study that included patients aged > 18 years with type 2 non-proliferative diabetic retinopathy (DR) and DME at baseline. All patients were treated with the ILUVIEN® implant. A minimum of two 6 × 6-mm OCTA scans were required to ensure that all cases had a baseline OCTA and an OCTA performed at 4 months of follow-up. Qualitative and quantitative comparisons were performed.
RESULTS: Ten eyes from ten subjects were included in the analysis. Mean (± standard deviation) age of the study cohort was 57.1 ± 8.3 years. Mean parafoveal perfusion density (PD) at baseline was 64.1 ± 1.8% at baseline, increasing to 66.1 ± 2.9% (p = 0.013) at the 4-month follow-up visit. Mean parafoveal PD at baseline was 64.4 ± 2.1%, increasing to 65.2 ± 2.6% (p = 0.024) after 4 months. In the qualitative assessment, 60 regions (10 areas for each subject) were graded to assess changes in retinal perfusion between the baseline and follow-up visits. This assessment revealed that 24 regions (40.0%) were characterized by a qualitative increase in perfusion after treatment, while 22 (36.7%) and 14 (23.3%) regions were featured by a stability and reduction in retinal perfusion, respectively.
CONCLUSIONS: OCTA analysis detects improvements in macular perfusion after treatment with ILUVIEN®. This improvement in macular perfusion may be associated with corticosteroid-related beneficial effects on leukostasis.
METHODS: This was a retrospective cohort study that included patients aged > 18 years with type 2 non-proliferative diabetic retinopathy (DR) and DME at baseline. All patients were treated with the ILUVIEN® implant. A minimum of two 6 × 6-mm OCTA scans were required to ensure that all cases had a baseline OCTA and an OCTA performed at 4 months of follow-up. Qualitative and quantitative comparisons were performed.
RESULTS: Ten eyes from ten subjects were included in the analysis. Mean (± standard deviation) age of the study cohort was 57.1 ± 8.3 years. Mean parafoveal perfusion density (PD) at baseline was 64.1 ± 1.8% at baseline, increasing to 66.1 ± 2.9% (p = 0.013) at the 4-month follow-up visit. Mean parafoveal PD at baseline was 64.4 ± 2.1%, increasing to 65.2 ± 2.6% (p = 0.024) after 4 months. In the qualitative assessment, 60 regions (10 areas for each subject) were graded to assess changes in retinal perfusion between the baseline and follow-up visits. This assessment revealed that 24 regions (40.0%) were characterized by a qualitative increase in perfusion after treatment, while 22 (36.7%) and 14 (23.3%) regions were featured by a stability and reduction in retinal perfusion, respectively.
CONCLUSIONS: OCTA analysis detects improvements in macular perfusion after treatment with ILUVIEN®. This improvement in macular perfusion may be associated with corticosteroid-related beneficial effects on leukostasis.
摘要：
背景：本研究的目的是使用光学相干断层扫描血管造影术（OCTA）研究患有糖尿病性黄斑水肿（DME）并接受0.19mgILUVIEW®（氟轻松玻璃体内植入物）治疗的患者的黄斑灌注变化。
方法：这是一项回顾性队列研究，包括年龄>18岁的2型非增生性糖尿病视网膜病变（DR）和DME患者。所有患者均接受ILUNEN®植入物治疗。至少需要两次6×6-mmOCTA扫描，以确保所有病例在随访4个月时都有基线OCTA和OCTA。进行了定性和定量比较。
结果：分析中包括来自10名受试者的10只眼睛。研究队列的平均（±标准差）年龄为57.1±8.3岁。基线时的平均旁凹灌注密度（PD）为基线时的64.1±1.8％，在4个月的随访中增加到66.1±2.9％（p=0.013）。基线时的平均旁凹PD为64.4±2.1％，4个月后增加到65.2±2.6%(p=0.024)。在定性评估中，对60个区域(每个受试者10个区域)进行分级以评估基线和随访之间的视网膜灌注变化。这项评估显示，24个区域（40.0％）的特点是治疗后灌注的定性增加，而22（36.7％）和14（23.3％）区域的特点是稳定和减少视网膜灌注，分别。
结论：OCTA分析检测到ILUNEN®治疗后黄斑灌注的改善。黄斑灌注的这种改善可能与皮质类固醇相关的对白细胞淤滞的有益作用有关。
方法：这是一项回顾性队列研究，包括年龄>18岁的2型非增生性糖尿病视网膜病变（DR）和DME患者。所有患者均接受ILUNEN®植入物治疗。至少需要两次6×6-mmOCTA扫描，以确保所有病例在随访4个月时都有基线OCTA和OCTA。进行了定性和定量比较。
结果：分析中包括来自10名受试者的10只眼睛。研究队列的平均（±标准差）年龄为57.1±8.3岁。基线时的平均旁凹灌注密度（PD）为基线时的64.1±1.8％，在4个月的随访中增加到66.1±2.9％（p=0.013）。基线时的平均旁凹PD为64.4±2.1％，4个月后增加到65.2±2.6%(p=0.024)。在定性评估中，对60个区域(每个受试者10个区域)进行分级以评估基线和随访之间的视网膜灌注变化。这项评估显示，24个区域（40.0％）的特点是治疗后灌注的定性增加，而22（36.7％）和14（23.3％）区域的特点是稳定和减少视网膜灌注，分别。
结论：OCTA分析检测到ILUNEN®治疗后黄斑灌注的改善。黄斑灌注的这种改善可能与皮质类固醇相关的对白细胞淤滞的有益作用有关。
